CD37 Immunoconjugates for Potent B-Cell Tumor Killing

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for B-cell malignancies, such as those targeting CD37, face limitations including low efficacy, patient relapse, and risks associated with radio-immunoconjugates, while CD37 has not been considered a favorable target for antibody-drug conjugates due to poor internalization and low potency of existing agents.

Innovation Solution

Development of novel antibodies and immunoconjugates that specifically bind to CD37, inducing apoptosis, complement-dependent cytotoxicity (CDC), and antibody-dependent cell-mediated cytotoxicity (ADCC), utilizing non-cleavable linkers to deliver cytotoxic agents directly to CD37-expressing cells.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If radio-immunoconjugates are used to treat B-cell malignancies, then tumor growth inhibition is achieved, but severe myelosuppression and cardiopulmonary toxicity occur

Engineering Contradiction:

Improvetumor growth inhibitionVSAvoidmyelosuppression and cardiopulmonary toxicity

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent extracts the harmful radiation component from the therapeutic approach by developing antibody-drug conjugates that deliver cytotoxic agents without radioactive isotopes. The immunoconjugates consist of an antibody component targeting CD37 and a cytotoxic agent component, eliminating the need for radiation while maintaining tumor killing capability through direct cellular toxicity mechanisms.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent changes the fundamental parameter of the therapeutic modality from radio-immunoconjugation to antibody-drug conjugation. This parameter change transforms the mechanism of action from radiation-induced cell death to cytotoxic agent-mediated cell death, thereby maintaining anti-tumor efficacy while eliminating radiation-related toxicities such as myelosuppression and cardiopulmonary damage.

Inventive Principle:

Principle #35Parameter changes

2Productivity

If CD37-binding agents are used to treat B-cell malignancies, then apoptosis and cytotoxicity are induced, but poor internalization and low potency limit efficacy

Engineering Contradiction:

Improveapoptosis induction and cytotoxicityVSAvoidinternalization efficiency and potency

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The patent optimizes the binding parameters of the antibody component to achieve high-affinity interaction with CD37. By carefully selecting and engineering the antibody's binding site and affinity, the system enhances internalization efficiency and ensures sufficient drug delivery to trigger potent apoptosis and cytotoxicity in CD37-expressing malignancy cells.

Inventive Principle:

Principle #35Parameter changes

3Quantity of substance

If existing anti-CD37 antibodies are used, then binding to CD37 is achieved, but complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity are insufficient

Engineering Contradiction:

ImproveCD37 bindingVSAvoidcomplement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity

Core Design Contradiction:

Quantity of substanceVSProductivity

Solution Approach 1:

The patent creates a composite immunoconjugate system combining the antibody component with a cytotoxic agent component. This composite structure integrates the target-binding function of the antibody with the cell-killing function of the cytotoxic agent, synergistically enhancing both complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity compared to antibody alone.

Inventive Principle:

Principle #40Composite materials

Solution Approach 2:

The patent merges the functions of target recognition and cell death induction into a single conjugated molecule. The antibody component binds to CD37 and the cytotoxic agent component is covalently linked, combining binding affinity with cytotoxic activity to produce enhanced complement-dependent and antibody-dependent cell-mediated cytotoxicity effects.

Inventive Principle:

Principle #5Merging (Combining)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The novel CD37-binding agents demonstrate high potency in inducing apoptosis and cytotoxicity, effectively inhibiting tumor growth in vitro and in vivo, with improved efficacy compared to existing therapies.

Implementation Method 1

capable of inducing complement dependent cytotoxicity (CDC)

Methodology Applied

Scientific EffectComplement-dependent cytotoxicity:

Implementation Method 2

capable of inducing antibody dependent cell mediated cytotoxicity (ADCC)

Methodology Applied

Scientific EffectAntibody-dependent cell-mediated cytotoxicity:

Data Source

PatentUS12559566B2CD37-binding molecules immunoconjugates thereof

Publication Date: 2026.02.24 DEBIOPHARM INTERNATIONAL SA

AI summary

Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to CD37 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.